Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson
In a Nutshell
Dr. Chris Thompson explains that the gut functions as both a digestive and endocrine organ, where insufficient fiber intake causes gut bacteria to degrade the protective mucous layer, leading to reduced butyrate production and compromised tight junctions that trigger metabolic dysfunction. The most effective interventions combine time-restricted eating, fermented foods, and high fiber intake (25-35g daily) with resistance training, while GLP-1 medications and emerging endoscopic procedures like duodenal ablation and magnetic anastomosis offer significant weight loss but require ongoing lifestyle adherence to prevent weight regain and muscle loss. Early metabolic dysfunction can be detected through CGM monitoring, fasting insulin levels, and waist circumference measurements long before diabetes develops, making proactive intervention far more effective than waiting for clinical disease.
These notes were generated by AI and may contain inaccuracies.
There's all sorts of evidence that if you don't have a lot of fiber, your microbiome is not healthy. Feed your microbes. They need to be fed. And what they eat is fiber. That's what you want them eating. You want them eating fiber. And if you're not feeding them fiber, they'll eat your mucous layer. And we already talked about how thin that barrier is. And all of a sudden, they start eating your mucous layer. They're not producing the butyrate you need. And the butyrates needed to maintain the tight junctions. So, there's layers to this. It's like a snowball effect that if you're not feeding those micro the microbiome and keeping it healthy, you're going to run into all sorts of trouble.
Welcome to the Huberman Lab podcast where we discuss science and science-based tools for everyday life. I'm Andrew Huberman and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine. My guest today is Dr. Chris Thompson. Dr. Chris Thompson is a professor of medicine at Harvard Medical School. He is also the chief of interventional gastroenterology at Mass General Brigham in Boston. He is a renowned expert on the intersection of gastroenterology, metabolism, nutrition, and obesity medicine.
In today's episode, Dr. Thompson explains how to improve your gut health, including the roles of your diet, gut microbiome, and gastrointestinal motility, as well as how your gut communicates with the rest of your body, which of course includes the gut microbiome, but as you'll learn today, much more. Dr. Chris Thompson is a guest on this podcast because he's not just a GI tract and obesity medicine expert. He's also credited with having created an entire new field of treatments and perspectives on GI and metabolic health. So the knowledge he shares today is truly at the cutting edge and applicable. Which is why by the end of today's episode, you will have a clear understanding of how your gastrointestinal system works, and you will have a set of new modern evidence-based tools for improving and maintaining your gut health.
Before we begin, I'd like to emphasize that this podcast is separate from my teaching and research roles at Stanford. It is, however, part of my desire and effort to bring zero cost to consumer information about science and science related tools to the general public. In keeping with that theme, today's episode does include sponsors.
A lot of us hear these days about the gut microbiome, the gut brain axis. We hear about GLP drugs that help people lose immense amounts of weight and stop feeling this food noise thing and on and on. But could we start by just having a conversation about this tube that is the digestive tract and get real basic and just educate people a bit on what happens that stimulates them to want to eat, why perhaps for certain periods of day or night they don't want to eat and then what the passage of food through us looks like as a series of steps.
This is such a critical part of our biology and our lives. It's becoming more and more complex all the time. The gut does a lot of things. So, it's obviously involved in digestion, but it's also an endocrine organ. You can hear it called the second brain. There's a lot of different ways we think about the gut and it is compartmentalized and each area has a different job.
So, you first have, the esophagus and its job is to just kind of move the food into the stomach safely and it's thick. It has different lining so it can handle things that might be a little rougher and it pushes sequentially down into the stomach. So, it's taking that food bolus and driving it into the stomach and you can have all sorts of problems in your esophagus. So, each one of these organs has, things it's supposed to do and then things that it doesn't do well.
Sometimes people don't swallow well. It gets too tight at the bottom. There's a condition called achalasia where it's just the bottom of the esophagus doesn't relax. And so we have procedures we can do in my line of work where you can tunnel down in between the layers of that esophagus. It's very thin, a few millimeters you can tunnel down into there and cut that muscle to relieve the obstruction.
The symptoms of achalasia are inability to swallow. They feel like they're choking. So they'll swallow food, it'll get down and stop and then they'll feel pressure. They'll feel really uncomfortable. If they drank some fluid with it, it might start coming back up. It'll just stay there. And then sometimes they'll have to induce vomiting to remove it. It's very uncomfortable for them. And it's not a terribly common condition, but it's coming more and more frequent.
You can get that inability to swallow for other reasons actually that are far more common. Chronic heartburn. If someone has reflux, that burning sensation, that can damage the lining of the esophagus and it can lead to precancerous conditions called Barrett's esophagus, which is something that needs to be treated, looked at, and followed. But with time, it can actually cause scarring. So you get a stricture. So it's kind of very fibrotic tissue there. That's another reason why people might have difficulty swallowing.
Then you have the stomach next. First, what the stomach does is it stretches to accommodate and accept a meal. So it stretches. Normally it's like a tube in your abdomen. But then when you start to smell food, it starts stretching and becoming more like a bag. It can stretch, relax to accept that meal. And if it doesn't do that properly, it causes symptoms like nausea.
So then it accepts the meal and it has to do its job which is to break it down and pass it on. So that the stomach now isn't just transporting, it's breaking it down. And it does that mechanically. So the fundus the top of the stomach is holding that meal. That's what kind of stretched up to hold it. And then the rest of the stomach is working on it. So the body of the stomach next segment is breaking it down. It's grinding the food into smaller bits. Acid is part of this as well. The stomach secretes acid and then the bottom of the stomach called the antrum will push the food out slowly into the duodenum, that's the first part of the small bowel.
Satiety, satiation all becomes part of this because the stomach is what secretes ghrelin. And so this is part of your satiety signaling.
All sorts of problems with the stomach. Food might not leave as it should in the right timing. So it can happen due to ulceration in the stomach, scarring or something called gastroparesis where for a variety of reasons it might be postviral, it might be due to diabetes, neural hormonal origins of this, the stomach just doesn't empty as it should. People have nausea and vomiting with that and other problems.
Then you get into the small bowel and the small bowel's job now typically you do a little digestion so early on because you have pancreatic and biliary secretions going in there but its main job is going to be to absorb calories right so that's absorbing calories and moving it down it's very thin it's one cell thick has about the surface area of like a pickleball court.
The lining is one cell thick. That cell type is called enterocytes. They're pretty sturdy. They rely on more than just the cell itself to maintain that barrier. There's certain cells called goblet cells that produce mucin and that creates a nice thick layer there that help as another part of the barrier. They have something called tight junctions between the cells which are complex little structures that are part of that barrier as well. And there's immune cells in there. There's other elements to that barrier but it is one cell layer thick.
That's why the esophagus and stomach got a good job of processing that food so that it's safe to go down through the small bowel and be absorbed. All sorts of issues with the small bowel. Similarly you can have different diseases that affect that like celiac disease, Crohn's disease etc. different inflammatory conditions. And what we're learning now is it plays a central role in metabolic disease. And that's kind of what's very exciting is its role in obesity, diabetes, and other similar conditions.
And then eventually you have the colon and that's where your microbiome is the star. The colon's job is to usually just absorb water. Most of the nutrients are gone by then. But it does play an important role as well and it is working hand in hand with your microbiome to make sure that you're producing it's mostly butyrate that's mostly involved there where the microbiome is producing short chain fatty acids and one of them the most important probably is butyrate that has a lot to say about your metabolism as well that's involved in satiety signaling and you have a lot of GLP-1 produced in the colon again so you're getting these kind of endocrine function of your colon that's very involved and then it passes.
Diseases in the colon include colon cancer which is a big one. Colon cancer screening is important. People typically now think they moved the age back to 45 everyone should start getting screened to make sure they don't have cancer. You can do it different ways. There are genetic tests you can do like Cologuard and if you do that you have to do it every few years. You can do screening colonoscopy every 10 years if it's normal and there's other things you can do as well. CT colonography is not as common and other tests but those are the two most common. It's important to do that.
Colon cancer is the most frequent cause of cancer. The survival rates are definitely improving due to screening programs. Starting at 45 is better than many people who started at 50 and they wouldn't get till 55 or 60. If you have a family member that has had cancer, you want to start at 40 or if they were younger, you want to start 10 years younger than when they were diagnosed.
Things like Cologuard and other genetic tests are going to keep getting better and help because you don't have to have that kind of very uncomfortable screening procedure. Colonoscopy is not a great way to do screening. You shouldn't have to have a relatively invasive procedure to be screened for something. It should be something you just do a blood test or a stool study or something like that. And I think we're getting there with technology and that will definitely show dividends because you can have the colonoscopy to remove the lesion, which is something that we can do. It's a newer technique where we can actually go in and remove these very early cancers endoscopically. So, we call it organ sparing surgery. So, you don't have to actually remove a piece of the colon anymore. You can just take the lining where that precancer is residing. It's a complicated procedure, but it's easy for the patient. They keep their colon, they go home the same day.
I'd like to take a quick break and acknowledge one of our sponsors Element. Element is an electrolyte drink that has everything you need and nothing you don't. That means the electrolytes, sodium, magnesium, and potassium, all in the correct ratios, but no sugar. Proper hydration is critical for brain and body function. Even a slight degree of dehydration, can diminish your cognitive and physical performance. It's also important that you get adequate electrolytes. The electrolytes, sodium, magnesium, and potassium, are vital for the functioning of all cells in your body, especially your neurons or your nerve cells. Drinking Element makes it very easy to ensure that you're getting adequate hydration and adequate electrolytes.
My days tend to start really fast, meaning I have to jump right into work or right into exercise. So, to make sure that I'm hydrated and I have sufficient electrolytes, when I first wake up in the morning, I drink 16 to 32 ounces of water with an element packet dissolved in it. I also drink Element dissolved in water during any kind of physical exercise that I'm doing, especially on hot days when I'm sweating a lot and losing water and electrolytes. Element has a bunch of great tasting flavors. In fact, I love them all. I love the watermelon, the raspberry, the citrus, and I really love the lemonade flavor. So, if you'd like to try Element, you can go to drinkelement.com/huberman to claim a free Element sample pack with any purchase.
Today's episode is also brought to us by Lingo. Lingo is an everyday wearable that tracks your glucose 24/7. Glucose drives a lot of key processes that support energy, body composition, and long-term health. When glucose is constantly spiking and crashing, that's where we can start to see metabolic dysfunction. And over time, that can even progress to pre-diabetes. Right now, about 115 million adults in the US have pre-diabetes. Most don't know it, and a higher percentage of men have it than women do. Often, there aren't clear symptoms of pre-diabetes early on, so people don't tend to look into it. But the fact is that metabolic health is shaping how your body functions every day, whether you feel it or not. Tracking your glucose with Lingo can help you see how food, activity, and stress impact your glucose throughout the day. I personally have used Lingo, and it's been an invaluable tool for improving my metabolic health. If you would like to try Lingo, Huberman Lab listeners in the US and UK can save 10% on a 4-week plan. Just visit hellolingo.com/huberman for more information. Terms and conditions apply.
Couple questions that no doubt will resonate with people because they're fairly common and you'll tell me if they're of concern or not depending on the frequency. We'll start at the top of the GI tract. People will say sometimes that they eat and some of the food seems to go up their nose. They know this because if they blow their nose, they might get some food particulate. It sounds like something that's not entirely uncommon based on the number of questions I get about it.
That could be a variety of different things and this is the area that I do work in. So it can be an oral pharyngeal transfer problem where the hypopharynx is transferring food into the esophagus that can be ENT thing it can actually be functional medicine as well where you can work with a speech pathologist that teaches people how to swallow better. They might have to change the quality of the food they're eating to thicker food. They might have to turn a certain way to swallow and there's ways they can actually train people with bio feedback to learn how to swallow better because that part's still under your control a little bit.
The next thing that can contribute to that is if they have high tension in the first sphincter up above which is the upper esophageal sphincter. That's the sphincter that separates the top of your esophagus from your mouth basically. And that can have high tension. And what I see a lot is something called Zenker's diverticula. There's a few different little pockets that can form high up on your esophagus near that sphincter. There's different names for how they exactly occur. And with time and with age, this is like a herniation of mucosa through the muscle and it creates a pocket and that can actually trap food. So when people are eating, the food goes into the pocket and then comes back up or can go out their nose or sit in there which is very uncomfortable for them. That's another way you can have problems swallowing and that can be fixed very easily. We go in through the mouth actually make a tiny incision and just kind of take down the septum that's part of that pocket opening up the pocket so that the food can leave. So it's important to do it early too because people can actually this it looks like an inconvenience initially. It's an inconvenience. The problem is when people then aspirate and that food goes in the lung and then it can lead to scarring in the lungs and eventually it can really cause problems. So, it is something that should probably be taken seriously and looked at even though it sounds funny, it is something that can be a real problem.
There's a weird thing about GI tract and bowel movements in particular, which is the following. With babies, with puppies and to some extent with ourselves, but especially with babies and with puppies, we sort of because they can't speak, we have a couple of key readouts that we intuitively understand reflect their health. One is the color of their skin, the eyes, if eyes are looking glassy or tired, and their quality or lack thereof of their bowel movements, quality, frequency, etc. But then something happens where speech comes online and we get toilet trained and then everyone's responsible for understanding their own bowel movements. And then we're never really told what's healthy bowel movements but we all kind of know what's normal for us or not normal. I'd be lying if I didn't say these are important metrics of health.
Well, there's so much you can tell from bowel movements. The rule of thumb is, you don't want to have more than three a day and you don't want to go longer than three days without having a bowel movement. So that's kind of the general rule and you want it to be one formed bowel movement, or a couple. You don't want little tiny pebbles. That's called scybala stool and that's a sign something's going on.
There's a lot you can tell how much fiber are they taking. The World Health Organization published something in the Lancet years ago on fiber synthesis I think they called it and they found that the vast majority of population really doesn't especially western countries just are not getting enough fiber which is obviously concerning because that causes a lot of issues long term. But if you're having these scybala stools, if you are constipated, meaning you're having a bowel movement more than once every 3 days and they're hard stools, that's a sign you're not getting enough fiber. So that's one thing you really have to think about.
Additionally, there's other things you can tell after procedures. If a bowel movement is very dark, tarry, and shiny, that's sign you have blood in your GI tract. But in general, that's kind of the rule of thumb. Having more than three a day is probably leaning towards being too loose. And if you're not having one every three days, you're probably bound up and then you really have to think about fiber.
As I recall, the recommendations were for adult men 35 grams of fiber per day and for women 25. And obviously that's not accounting for variations in body weight and height and all the rest. So does that sound about right? Yeah, that's about right. And it kind of depends on the quality, too.
There's a couple other really interesting studies that came out recently just within the last few years looking at the importance of fiber related to certain conditions like one was fatty liver. And fatty liver it was an interesting study they were using resistant starch like level 2 so basically raw powdered potatoes something like that and they were supplementing it at 40 grams and they found that when they did that they actually saw a significant improvement in fatty liver which is phenomenal and it was relatively weight stable. So it has important treatment effects.
Another group actually studied it and looked at insulin sensitivity. So they did clamp studies where they would really be able to detect insulin resistance and kind of try to look at glucose utilization and clearance. And they found that with this RS2 type, resistant starch 2, they were able to improve insulin resistance and insulin sensitivity as well. So fiber is very important. It's not just about the bowel movements. It's also about really just having health.
It probably helps the microbiome. There's all sorts of evidence that if you don't have a lot of fiber, your microbiome is not healthy. You get less diversity in your microbiome. The different studies that have looked at that. It is important to have that fiber and that constipation is an early window into it. It's an early sign that maybe you're not getting enough fiber.
I make it a point to eat fruits and vegetables because I like them. But recently, I started supplementing with a powdered psyllium husk that and some of them actually taste pretty good and my expectation was I was going to feel really bloated. It was quite the opposite. It not that I had gut issues before, if it was normally kind of like hypernormalized things actually it made post meal subjectively the sensation just like feel good feel great and I didn't expect that I thought okay more fiber I think a perception people have is like more fiber more regularity and more bloat.
And I think that's a that might be true for some people but it certainly wasn't my experience and I think that if I feel like the messaging on fiber to the general public is pretty lousy meaning people are told to take it that's great. They're told all the time, but I think people think, "Oh, if I have a lot of fiber, I'm going be really gassy. I'm going to be really bloated." But as you point out, it's not just about regularity and speed of digestion. It's about creating a healthy milieu for the gut. I think if more people knew that, they'd probably make a move to consume more fiber.
Totally. It's like feed your microbes, or they're going to eat you. And it's kind of true, because they need to be fed. And what they eat is fiber. That's what you want them eating. You want them
Without adequate fiber intake, gut bacteria consume the mucous layer lining the digestive tract. This protective barrier is already thin, and when bacteria degrade it, they stop producing butyrate. Butyrate is essential for maintaining tight junctions between intestinal cells. The process creates a snowball effect where neglecting microbiome health through insufficient fiber leads to cascading problems throughout the digestive system.
During fasting periods, the microbiome begins consuming the digestive tract lining. However, research indicates a rebound effect often occurs afterward, potentially leaving the microbiome in a slightly improved state. For individuals experiencing gut issues, avoiding prolonged empty stomach periods outside of sleep may be advisable. However, the benefits of time-restricted eating and intermittent fasting likely outweigh this potential risk. Giving the pancreas time to rest and allowing insulin levels to decrease is particularly important, as frequent eating keeps insulin levels chronically elevated.
Early research suggested consuming calories in the morning due to a cortisol spike, but this may not hold true. Consuming food earlier in the day and beginning the fasting window in the afternoon may be more beneficial. The key principle is that implementing some form of time-restricted eating is better than not doing it at all.
Low-sugar fermented foods like kimchi, sauerkraut, and brine have demonstrated benefits for microbiome diversity and reduced inflammatory markers. Research comparing fermented foods to fiber showed that fermented foods improved microbiome diversity and lowered inflammation, while fiber alone did not produce these effects.
Fermented foods serve multiple functions: they act as prebiotics by feeding beneficial bacteria with partially digested compounds, and they provide live probiotic cultures including bifidobacteria and lactobacilli. This combination helps establish healthy bacterial populations similar to planting seeds while providing fertilizer for growth.
Butyrate cannot be effectively supplemented directly because it doesn't reach the colon intact. Instead, bacteria produce it through cross-feeding: initial bacteria break down fiber into acetate and lactate, which other bacteria then convert into butyrate. This process feeds colon cells, maintains tight junctions, activates GLP-1 and satiety pathways, and creates an acidic environment that inhibits pathogenic organisms.
Barry Marshall proved H. pylori causes gastric ulcers through self-experimentation, consuming the bacterium and subsequently developing ulcers. H. pylori was found in Ötzi the Iceman, a 5,000-year-old specimen discovered in the Italian Alps, indicating this bacterium has affected humans for millennia.
While H. pylori is one cause of ulcers, stress can increase acid production. In gastric bypass patients, ulcers often result from relative ischemia due to type 2 diabetes or smoking, or from connecting the stomach pouch to distal small bowel lacking pancreatic bicarbonate for acid neutralization. When the gastric bypass pouch is too large, it produces acid that the jejunum cannot naturally defend against. Multiple factors typically contribute to ulcer formation rather than a single cause.
GLP-1 medications represent a significant advancement in treating obesity and related metabolic issues. However, adherence remains problematic, with approximately 30% of patients discontinuing within the first month and 50% by year's end. This pattern mirrors medication adherence issues across various drug classes.
Primary discontinuation factors include needle fatigue from weekly injections, difficulty remembering daily oral medications, side effects during dose escalation including nausea, and concerns about long-term effects of super-physiologic dosing. Over 85% of patients seeking endoscopic therapies have previously used or are currently using GLP-1 medications.
Microdosing involves using insulin syringes to administer smaller doses than standard protocols, often by transferring medication from injection pens to sterile vials. This approach allows personalization of dosing, potentially reducing side effects while maintaining weight loss benefits. Microdosing may be particularly useful for maintenance after achieving weight loss goals, avoiding the need to completely discontinue medication.
Approximately one-third of weight lost on GLP-1 medications consists of lean mass, primarily muscle. Cycling on and off these medications leads to progressive deterioration of body composition, as weight regain consists primarily of fat rather than muscle. This creates increasingly unfavorable body composition with each cycle of use and discontinuation.
Resistance training helps maintain muscle mass during caloric deficit by signaling to the body that muscle tissue is needed. This principle applies across GLP-1 medications, earlier weight loss medications, and surgical or endoscopic procedures.
Reported side effects include increased apathy and reduced appetite for food, alcohol, and life activities. A rare but serious complication involves blindness in individuals with specific optic nerve head ischemic vulnerabilities. This affects a very small subset of users who should be screened for this structural eye condition before treatment.
Muscle loss, including visible changes like "Ozempic face" and "Ozempic butt," represents a major concern. Some patients develop sarcopenia, particularly those with low baseline muscle mass or minimal exercise during treatment. Nausea at higher doses prevents weight loss at tolerable lower doses for some patients.
Bariatric surgery originated in the 1950s at the University of Minnesota with jejunoileal bypass procedures designed to create malabsorption. These early procedures created blind limbs leading to bacterial overgrowth, calcium-oxalate binding issues, and renal failure, making them highly problematic despite weight loss benefits.
Gastric bypass, developed by Mason in the mid-to-late 1960s, aimed to avoid jejunoileal bypass complications while maintaining treatment efficacy. The procedure was conceptualized as combining restriction through stomach size reduction with malabsorption through intestinal bypass, though actual mechanisms differ from original theories.
Later developments included adjustable gastric bands (purely restrictive), vertical banded gastroplasty (true stomach stapling), and sleeve gastrectomy. All procedures were initially designed around restriction or malabsorption concepts but function through mechanisms different from original intentions.
Physicians have significant incentives to develop new procedures beyond ego, including the prestige of having a procedure named after them that saves lives. This motivation combines with the practical reality that hands-on familiarity with tissue, gained through direct manipulation, recording, slicing, and microscopic examination, provides physicians with unique insights that complement theoretical knowledge. When patients return with specific complaints like persistent hunger or localized pain on the left side, this deep tissue familiarity helps physicians understand what the pain could indicate.
The proper regulatory channels for developing new procedures are workable, though they do slow down the process. Compassionate use cases exist with expedited protocols for exceptional circumstances. One documented case involved a patient with chronic bleeding that couldn't be stopped, where a device approved in Canada but not yet in the United States was obtained within 12 hours through compassionate use approval, successfully treating the patient.
Devices approved for one indication are frequently used off-label in clinical practice, similar to how drugs are used off-label. For example, wires designed for vascular indications are routinely used to access bile ducts for stone removal, despite never being officially approved for that specific use. This practice relies on clinical judgment and has been standard practice in hospitals for decades.
AG1 launched their newest formulation called AG1 Pro, which adds three new ingredients to their clinically backed formula: 5 grams of creatine monohydrate for muscle strength and brain health, calcium HMB for muscle recovery and reduced muscle breakdown, and zinc carnosine to support gut lining. The sponsor offers 20% off the first subscription at drinkag1.com/huberman using code backtoine.
Ghrelin is the primary hunger hormone produced in the fundus (top thin part) of the stomach where the esophagus connects. When ghrelin levels rise, it travels to the brain to stimulate hunger. After eating, ghrelin drops and returns sometime after the meal. This hormone is actively used as a mechanism in both endoscopic and surgical weight loss procedures.
CCK (Cholecystokinin) is secreted from the first part of the duodenum and serves dual purposes: it causes the gallbladder to release bile while also acting as a satiety signal. Peptide YY and GLP-1 are major satiety hormones produced by L cells in the distal small bowel and colon. GLP-1 is particularly triggered by glucose, while Peptide YY responds more to proteins and fats, promoting longer satiety especially after heavy fat and protein meals.
GIP (Gastric Inhibitory Polypeptide) from K cells functions similarly to GLP-1 but is less potent, often described as "Batman and Robin" with GLP-1. The drug retatrutide, which promotes GLP-1, GIP, and glucagon simultaneously, showed a 30% body weight reduction in clinical trials. GIP appears to help reduce nausea, allowing higher GLP-1 doses, and contributes to insulin sensitivity. Glucagon's inclusion may provide muscle-sparing effects while promoting fat burning.
Twenty years ago, there were virtually no effective pharmaceutical options for obesity treatment. The available treatments were primarily stimulant-based, including phentermine (a sympathomimetic) and fenfluramine, which was associated with valve issues. Nicotine has reemerged in oral forms as an appetite suppressant, though it raises blood pressure and carries high addiction potential.
A Bethesda NIH study with 20 subjects using crossover design found that participants eating processed foods consumed approximately 500 more calories per day compared to whole foods when eating ad libitum. Processed foods are easier to digest, cause larger glucose spikes, have lower thermogenic effects, and contain less fiber, negatively impacting the microbiome.
Leptin, secreted from fat cells in proportion to fat mass, functions as a metabolic thermostat. High leptin generally signals reduced eating, while low leptin increases appetite. However, leptin resistance develops in obesity due to chronic high levels, receptor saturation, and low-grade inflammation in the hypothalamus and brain tissue. This resistance explains why leptin-based drug development largely failed despite initial excitement following its discovery and cloning.
The incretin concept originated in 1930s London when researchers ground up animal duodena, emulsified the tissue, and injected it back into the vascular system. They observed that blood glucose fell, leading to the hypothesis of an "incretin" (building on the known hormone secretin) that caused glucose reduction.
Sheila Sherlock's laboratory in London later demonstrated the incretin effect by comparing insulin responses to identical glucose loads given intravenously versus orally, finding significantly more insulin production with oral glucose. This suggested a duodenal factor was responsible.
Dr. Bell at Lily Labs cloned pre-proglucagon, leading to identification of both GLP-1 and GLP-2. Dr. Bloom in London confirmed GLP-1's presence in the bowel, demonstrated that glucose intake increased circulating GLP-1, and showed that GLP-1 infusion raised insulin and lowered glucose.
The major obstacle was GLP-1's rapid degradation by dipeptidyl peptidase, requiring continuous infusion. In the 1990s in the Bronx, Dr. Eng discovered exendin-4 in Gila monster venom, which closely resembled GLP-1 with a single amino acid substitution and longer C-terminus, becoming the basis for all current GLP-1 medications.
After developing improved biopsy needles for pancreatic cancer diagnosis during fellowship in Boston, the focus shifted to metabolic disease. The initial company addressed the 50/50 diagnostic success rate of standard FNA needles, which were designed for delivery rather than tissue extraction. A new bevel design was developed that could bind to pancreatic tissue without causing pancreatitis, enabling earlier diagnosis and precision medicine applications including drug response testing and immunostaining.
Medical diagnostics currently focus on "reading" from the body through measurements like sleep scores, heart rate, and blood pressure. However, structural interventions allow physicians to directly observe and potentially modify the body's architecture. The concept of comprehensive, minimally invasive biopsies of major organs through natural orifices raises questions about proactive health screening versus waiting for symptomatic presentation.
Biopsy procedures have become dramatically more affordable over time. The challenge with biopsies is the need for precise targeting to obtain the relevant tissue. Even when in the correct area, such as a pancreatic lesion, cancer cells may not be captured. Once tissue is obtained, comprehensive analysis becomes possible including staining to identify genetic predispositions and drug response predictions.
Procedure-based treatments offer significant advantages over traditional surgery, particularly when accessing the body through natural openings rather than incisions. However, diagnostic procedures face scalability challenges because they require dedicated physician time per patient, creating bottlenecks when screening large populations.
The preference is for diagnostics to become progressively less invasive to enable broader scaling. Ideal solutions include smartphone-based AI analysis, minimally invasive imaging, and blood tests that can be performed quickly and easily. Several metabolic health assessments could currently be done non-invasively at home to detect issues much earlier than traditional methods allow.
Hemoglobin A1C serves as the standard diabetes marker, but metabolic dysregulation follows a predictable sequence that can be detected much earlier. The Whitehall 2 study, a prospective longitudinal study of British civil servants, demonstrated that high fasting insulin predicted diabetes development 10-15 years before onset. The NHANES study revealed that less than one-third of lean people are metabolically healthy, with only 12% of the total population meeting metabolic health parameters based on waist circumference, glucose, blood pressure, and other markers.
Calorie excess represents the first stage, typically involving excess glucose and saturated fat in Western diets. A continuous glucose monitor (CGM) can detect glucose spikes to specific foods, revealing sensitivities that may warrant dietary adjustments.
High fasting insulin follows as the next phase. Insulin's role is to move glucose from the bloodstream into cells, as elevated glucose causes damage through glycation and vascular complications. Fasting insulin testing is inexpensive and can identify chronically elevated levels often caused by frequent eating or high glycemic foods.
Ectopic fat develops when fat accumulates in cells not designed for storage, such as liver, muscle, and pancreas cells, as opposed to subcutaneous fat (energy depot), visceral fat (omentum and mesentery), or organ-associated fat (around heart and kidneys).
Waist circumference, waist-to-height ratio, DEXA scans, CT scans, MRIs, and ALT liver enzyme measurements can indicate ectopic fat accumulation. Insulin resistance can be calculated using a formula involving fasting blood glucose and fasting insulin levels, where values greater than 2 indicate insulin resistance.
Metabolic inflexibility represents the final stage where the body loses its ability to efficiently switch between fuel sources. During fasting, the body should burn fat stores but instead relies on glycogen or muscle tissue. During eating, it fails to properly shift to burning carbohydrates. This condition increases likelihood of weight gain, obesity, and beta cell apoptosis leading to reduced beta cell mass.
Metabolic flexibility can be assessed through respiratory exchange ratio testing using breath analysis equipment that measures carbon dioxide to oxygen ratios. When burning carbohydrates, the ratio approaches 1.0 due to equal carbon and oxygen content. Fat burning requires more oxygen, producing ratios around 0.7. Athletes use this testing for performance optimization, and home testing devices are becoming available.
Function provides over 160 advanced lab tests covering heart health, hormone health, autoimmune function, and nutrient levels, plus access to advanced MRI and CT scans. Results include physician recommendations for health improvement. A membership costs $365 annually ($1/day) with a $50 credit available using code "huberman" at functionhealth.com/huberman.
Medical practice evolves slowly, requiring multiple randomized controlled trials and meta-analyses before adopting new approaches. Patients seek affordable data access now rather than waiting for formal validation. CGMs faced initial physician resistance due to concerns about patient anxiety over normal glucose fluctuations, but acceptance has grown significantly. Similar patterns are expected with whole-body MRI and other diagnostic technologies.
Early action on metabolic dysfunction yields better treatment outcomes than waiting for diabetes diagnosis, when beta cell mass may already be compromised along with peripheral nerve function. CGMs provide actionable dietary insights that help prevent insulin spikes, though saturated fat concerns must be balanced against ApoB levels.
Physician concerns about patients accessing their own data include fears of misinterpretation leading to inappropriate dietary choices. However, individuals seeking CGM data are typically motivated to improve health. More diagnostic information is generally beneficial, provided follow-up confirmatory testing methods improve to reduce risks associated with additional procedures.
New medical procedures face adoption challenges even after FDA approval due to training requirements that cannot be completed in weekend courses. Physicians may complete abbreviated training and perform procedures inadequately, creating reluctance among referring doctors. Insurance coverage often serves as validation before widespread adoption occurs.
AI applications in medical procedures include real-time coaching through earbuds or heads-up displays that highlight anatomical structures, guide stitch placement, and count sutures during procedures.
AI can count stitches in real time during procedures and assess whether they are placed close enough together. The system can change the shape of the stomach during surgery to provide immediate feedback on treatment effectiveness. This represents a level of real-time guidance that was previously impossible.
Robotics can dramatically shorten the learning curve for complex procedures. In randomized studies, trainees learning colon tumor resection spent weeks training in both traditional and robotic methods. Those using the traditional approach struggled significantly, as these procedures typically require two to three years to master. Trainees using robotics achieved near-expert performance levels after minimal training time.
When intuitive surgical robots were first introduced years ago, they democratized surgical outcomes by elevating mediocre surgeons to excellent performance levels while maintaining excellent surgeons at their existing level. The technology particularly benefited surgeons who were previously struggling.
Volume of procedures performed serves as an important metric for evaluating surgeon expertise, including both current case volume and historical case volume. Medicine needs to shift toward objective metrics rather than relying on subjective assessments.
The Everself healthcare delivery platform collects data on procedure outcomes, stitch counts per procedure, procedure time, and complications. AI analysis can grade performance by distinguishing full-thickness sutures versus partial-thickness sutures, with a target of 100% full-thickness placement. The system can assess suture spacing patterns, stomach volume reduction, and provide specific grading at procedure completion.
Adenoma detection rates in colonoscopy were previously published as a quality metric. This created access problems where patients sought only the highest-performing doctors, resulting in extremely long wait times. There should be reasonable thresholds for expertise while ensuring patient access.
Eye surgeons previously performed procedures for approximately 100 years without contrast agents like fluorescein, relying solely on intuition and training to distinguish healthy from unhealthy tissue. The introduction of contrast agents dramatically improved safety margins and outcomes.
AI systems are trained on thousands of procedures, exceeding any individual surgeon's experience. Pattern recognition enables AI to identify structures like blood vessels that are difficult to see. Surgeons must maintain clinical judgment and can override AI suggestions. For procedures like peroral endoscopic myotomy for achalasia, AI can color-code blood vessels to reduce vessel injury risk during tunneling.
Endoscopic ultrasound produces grayscale images without color differentiation. Previous attempts at image registration with CT-PET scans required three hours of preparation and could not be scaled. AI is now automating this process for diagnosis and potentially therapy guidance.
Hyperspectral imaging uses multiple narrow wavelength bands to create tissue fingerprints, allowing tumor margin identification without dyes. Groups in London are conducting this work using advanced LED technology and CMOS chips that can read fluctuating light wavelengths faster and more accurately than traditional CCD chips.
Our Place produces toxin-free cookware, addressing the presence of PFAS (forever chemicals) in 80% of non-stick pans. Their Titanium Always Pan Pro uses pure titanium without chemical coatings, maintaining non-stick properties without degradation. The pan is dishwasher-safe and suitable for eggs, burgers, and steaks.
Medical diagnostics have progressed from examining bodily outputs to surface observations to increasingly sophisticated imaging. Blood tests represent current non-invasive diagnostic approaches. The goal continues to be obtaining more diagnostic information with less invasive procedures.
Treatment strategies include either addressing pathology directly or augmenting normal physiology. GLP-1 medications represent physiologic augmentation rather than treating a deficit, as these compounds are administered at super-physiologic doses far exceeding natural levels. Natural GLP-1 is nutrient-responsive, secreted from L cells in response to meals in small amounts, affecting insulin production, gastric emptying, and satiety signaling.
A patient with gastric bypass anatomy developed a fistula between the gastric pouch and remnant stomach. Endoscopic closure of this fistula resolved reflux symptoms and unexpectedly led to renewed weight loss and diabetes resolution. This observation occurred in 2003-2004 and initiated investigation into gut hormone mechanisms.
Research using GK diabetic rats without obesity tested foregut exclusion versus hindgut stimulation. Rats with foregut exclusion showed significant diabetes improvement, while those without exclusion showed no improvement despite hindgut stimulation. This suggested the presence of an anti-incretin factor in the foregut that, when excluded, produces better treatment effects.
Normal individuals show different insulin responses to intravenous versus oral glucose administration. Diabetic patients lack this incretin response. Research linked this phenomenon potentially to GLP-1 and intestinal mechanisms, supporting the importance of foregut exclusion in diabetes treatment.
Endoscopic placement of a duodenal liner (sleeve anchored in the proximal small bowel) achieved one-point A1C reduction and 7% total weight loss in diabetic patients. The device functions by preventing mixing of food with digestive enzymes for several feet, though it requires eventual removal as an implant.
The liner is positioned immediately after the pylorus, allowing digestive secretions to flow outside the sleeve while food travels inside. This creates compartmentalization that prevents enzyme-food mixing in the proximal small bowel.
A Brazilian cardiologist developed a novel experimental surgery called ileal interposition for lean type 2 diabetic patients. The procedure takes the distal small bowel and moves it up near the duodenum while preserving mesenteric blood flow. The concept is that GLP-1 is denser in the distal bowel, and moving it proximally creates a more immediate incretin effect by hitting GIP first, then GLP-1 immediately afterward.
The results were remarkable: patients' diabetes resolved without any weight loss since there was no restriction or absorptive change. The food pathway remained unchanged.
A cardiologist colleague proposed ablating the duodenum to reset stem cells rather than attempting the endoscopic ileal tissue harvesting approach. The duodenum in patients with metabolic disease is considered "sick," and ablating it may reset the stem cells. This procedure requires no sleeve or bowel rerouting.
Clinical outcomes show A1C drops by over one point without significant weight loss. Studies suggest this treatment may prevent weight regain when patients discontinue GLP-1 medications by resetting duodenal stem cells and healing tight junction problems.
Mouse studies demonstrated that overfed mice develop longer, heavier bowels with longer villi compared to control mice. Human studies using gastric bypass patients and cancer surgery controls showed similar findings: people with obesity or type 2 diabetes have longer, thicker villi with significantly more inflammation.
Natural killer cells are upregulated eightfold and macrophages 1.5-fold in these patients. Immunohistochemical staining reveals lower levels of disorganized tight junction proteins including zonula occludens and scaffolding proteins.
Tight junctions function to keep contents within the gut lumen and prevent bacteria from entering systemic circulation. Increased gut permeability is scientifically validated, though the term "leaky gut" carries problematic connotations in medical communities due to associations with various unsubstantiated symptom clusters.
Organoid studies from small bowel biopsies of MASH patients revealed poorly developed, disorganized tight junctions compared to controls. Transcriptomics confirmed these patients weren't producing RNA for tight junction proteins, indicating transcriptional downregulation.
Patients with MASH showed significantly higher absorption of 51-chromium EDTA tracer compared to controls and treated celiac patients, indicating increased gut permeability. This is particularly significant because gut-derived substances travel directly to the liver via portal circulation.
Lipopolysaccharide (LPS) from gram-negative bacteria that crosses compromised tight junctions triggers inflammatory cascades via TLR4 and NF-κB signaling. A Duke University study injected LPS into healthy volunteers and demonstrated dramatic increases in inflammatory markers and induction of insulin resistance.
Maintaining microbiome health through fiber and fermented beverages is critical for producing healthy enterocytes and tight junctions, as well as maintaining a healthy mucin layer. Butyrate and microbial byproducts interact with the innate immune system to regulate recognition of bacterial populations.
Artificial sweeteners are preferable to high fructose corn syrup. Fructose in beverages creates a rapid hepatic burden compared to fructose in whole fruit, which comes with a protective matrix. The concern with artificial sweeteners relates primarily to their presence in highly processed foods rather than inherent toxicity.
Polyunsaturated fats have evidence supporting LDL reduction and health benefits, though oxidation from prolonged storage or repeated deep frying creates trans fats. Olive oil is universally recognized as beneficial, with small amounts of butter acceptable. The omega-3 to omega-6 ratio concern appears overstated; minimal omega-3 intake from occasional fatty fish consumption appears sufficient.
Omega-3 data for metabolic and cardiovascular health is mixed, though evidence suggests greater benefit for Alzheimer's prevention. Supplementation should address documented deficiencies rather than universal application. Vegetarians can obtain omega-3s from algae, the original source, rather than fish.
All patients receive recommendations for resistance training before weight loss procedures. Zone 2 cardio supports fat burning, while high-intensity interval training mobilizes visceral fat through beta-adrenergic and gonadotropic hormone receptor activation. Visceral fat mobilizes during acute stress but isn't immediately burned during HIIT since carbohydrates are the primary fuel source at that time.
Weight is defended within a range rather than at a specific point, regulated by leptin, thyroid hormones, and other factors. Crash dieting triggers multiple compensatory mechanisms: reduced energy expenditure from smaller body size, downregulated satiety hormones (GLP-1, PYY, CCK), elevated ghrelin, and 25% increased muscle efficiency. The Biggest Loser study demonstrated participants burned 500 fewer calories daily post-weight loss.
Developed in 2012, ESG involves endoscopic stomach folding to create a smaller gastric pocket that triggers stretch receptors more rapidly, sending vagal afferents to the NTS and hypothalamic satiety centers. Additionally, food retention in the stomach suppresses ghrelin production. This dual mechanism facilitates sustained weight loss by addressing ghrelin elevation that typically follows dietary weight loss.
Endoscopic ablation of ghrelin-producing cells in the gastric fundus using argon plasma coagulation can suppress ghrelin levels. This procedure is performed in Germany where physicians can access the mucosal layers of the fundus. The technique involves spraying argon plasma over the fundus to eliminate ghrelin-producing cells. These cells grow back but in reduced numbers. When combined with DSG (duodenal sleeve gastroplasty), weight loss increases from approximately 18% with DSG alone to over 20%, potentially reaching 25% when ghrelin ablation is added.
A magnetic anastomosis procedure was developed to connect the first part of the jejunum to the lower part of the ileum using ring magnets encased in nitinol. The magnets are delivered through endoscopes - one from above through the stomach into the jejunum and one from below via colonoscopy into the ileum. Once positioned, the magnets form rings that create an anastomosis allowing food to pass directly between these sections. This procedure creates significant GLP-1 spikes by enabling direct hindgut stimulation.
Current approaches combine magnetic anastomosis with endoscopic suturing procedures to replicate the effects of gastric bypass surgery. These combined procedures provide GLP-1 hindgut spikes, gastric restriction, vagal afferent signaling, and ghrelin suppression. The goal is to target specific aspects of gastric bypass effects through minimally invasive approaches rather than performing the full open procedure.
The conversation identifies a parallel between medication development and procedural approaches. While GLP-1 drugs like Ozempic and Mounjaro dramatically increase GLP-1 levels, newer medications like retatrutide combine GLP-1 with GIP and glucagon system activation, resulting in better weight loss outcomes and muscle preservation. This suggests that pushing too hard on single biological levers may be less effective than combinatorial approaches that target multiple systems simultaneously.
Endoscopic procedures can be combined with medications to enhance outcomes. For example, performing gastric tightening procedures followed by GLP-1 medications may achieve greater weight loss at lower drug doses. This multimodal approach mirrors strategies used in ADHD treatment where behavioral and nutritional interventions combined with lower medication doses may reduce side effects while maintaining efficacy.
The Look AHEAD study demonstrated that diet and exercise alone achieved only 6% total weight loss at 10 years with no improvement in heart disease outcomes. However, this doesn't mean lifestyle interventions are irrelevant. When patients undergo gastric bypass, endoscopic procedures, or GLP-1 medications, they must still address underlying problems including increasing fiber intake, improving diet quality, avoiding insulin spikes, and incorporating regular exercise. Without these foundational changes, all treatments will ultimately fail.
A gene therapy approach uses viral vectors containing the GLP-1 gene with the beta cell insulin gene promoter. This enables nutrient-responsive GLP-1 secretion that occurs simultaneously with insulin release. The viral vectors are delivered via endoscopic ultrasound injection into the tail of the pancreas, targeting beta cells specifically. This approach creates paracrine GLP-1 production directly at the pancreas rather than requiring transport from intestinal L-cells.
Pancreatic cells are terminally differentiated, meaning the episomal DNA remains stable without integration into host DNA. This provides permanent GLP-1 production capability. Clinical trials began in the Netherlands, representing a potential one-time treatment for sustained GLP-1 elevation. The therapy could be used alone or to augment gastric and small bowel procedures.
Gene therapy shows promise for conditions like Prader-Willi syndrome where hypothalamic signaling deficits cause hyperphagia. Traditional GLP-1 drugs have not been effective for these patients. In mouse studies, the gene therapy transgene achieved weight loss comparable to high-dose semaglutide, with treated mice maintaining stable weight rather than continued loss, and preventing weight regain when semaglutide was discontinued.
Dr. Thompson describes himself as a tinkerer who took apart motorcycles in high school and modified car parts. This hands-on approach influenced his decision to pursue interventional gastroenterology rather than general internal medicine. He emphasizes the importance of addressing underlying problems rather than managing chronic conditions with medications alone, noting that while mortality from heart disease has been reduced, rates of fatty liver and diabetes continue to rise.
Dr. Thompson emphasizes that all innovations result from team efforts rather than individual work. He consistently gives credit to colleagues and recognizes that progress in medical innovation requires collaborative approaches across multiple disciplines and institutions.
Keep Andrew Huberman in your library
Save the videos and channels worth coming back to, and find them again in one place.
